Back to search

Article

SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses

2021-03-12

Abstract excerpt

<h4>Background</h4> The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 110 million individuals and led to 2.5 million deaths worldwide. As more individuals are vaccinated, the clinical performance and utility of SARS-CoV-2 serology platforms needs to be evaluated. <h4>Methods</h4> The ability of four commercial SARS-CoV-2 serology platforms to detect previous infection or vaccinatio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f8d41474-5fdb-5acd-88ad-4adc1507455b
DOI
10.1101/2021.03.10.21253299
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune ResponsesDOI 10.1101/2021.03.10.21253299
Anti-SARS-CoV-2 antibody levels are concordant across multiple platforms but are not fully predictive of sterilizing immunitySemantic proximity
Increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: an update from the COV-AD studySemantic proximity
Evaluation of a novel fully automated and ELISA- based assays for detecting anti- SARS- CoV-2 neutralizing antibodiesSemantic proximity
Seroincidence of SARS-CoV-2 infection prior to and during the rollout of vaccines in a community-based prospective cohort of U.S. adultsSemantic proximity
IMMUNO-COV™ v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody TitersSemantic proximity
SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunitySemantic proximity
Observational Report on Functional SARS-CoV-2 Immune Responses in Immune Competent and Compromised IndividualsSemantic proximity
Quantifying post-vaccination protective anti-SARS-CoV-2 IgG antibodies in blood and saliva with a fully automated, high throughput digital immunoassaySemantic proximity
In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variantSemantic proximity
Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS StudySemantic proximity
Rapid, High Throughput, Automated Detection Of SARS-Cov-2 Neutralizing Antibodies Against Native-Like Vaccine And Delta Variant Spike TrimersSemantic proximity
Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunitySemantic proximity
Select a neighboring publication to make it the new centre.